Clasp Therapeutics’ novel T cell engagers could offer advantages over others in this class of cancer immunotherapies. The startup is based on the research of Johns Hopkins University scientist Bert Vogelstein.
AbbVie will take the lead on commercializing Regenxbio’s gene therapy in wet AMD and diabetic retinopathy. It’s AbbVie’s second major gene therapy deal this year, coming months after it committed $90 million to preclinical-stage Capsida Biotherapeutics.
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
FDA approval of Supernus Pharmaceuticals drug Qelbree gives attention-deficit hyperactivity disorder patients another treatment option that is not classified as a Schedule II substance. It’s a different formulation of a drug that was first approved in Europe decades ago.
Pfizer, which had been running the trial of rivipansel in SCD, reported that it had failed on its primary and key secondary endpoints.
In a conference call with analysts, the company's CEO was tight-lipped about the median improvement in PFS, but the results nevertheless beat many investors' expectations.
Two trials involving the drug MGD009 - a monotherapy study and one in combination with the company's PD-1 inhibitor - are barred from enrolling new patients pending FDA review and a planned protocol amendment.
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
A new analysis from Rockville, Maryland-based Cryptonite found that ransomware is on the rise. While there were 19 healthcare ransomware events reported to HHS/OCR in 2016, there were 36 in 2017.
Abilify MyCite, developed in collaboration between Proteus Digital Health and Otsuka Pharmaceutical, has an ingestible sensor embedded in the pill which records that the medication was taken. It reflects a trend by companies to use sensors to quantify the effectiveness of medications.
Among the technologies in Relevant Health's seven-member inaugural class are wearables to reduce back injury risk and reducing seniors' fall risk.
In exchange for a $50,000 investment, Relevant Health takes up to an 8 percent equity stake.
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
Hospitals are improving their patient safety track record, particularly when it comes to reducing the pressure ulcers that can result in complications like infections and lengthened hospital stays. A report released this week by Agency for Healthcare Research and Quality showed a 17 percent decline in hospital-acquired conditions from 2010 to 2013. Last year alone, […]